Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.

Leon, Otilia; Guren, Marianne G; Radu, Calin; Gunnlaugsson, Adalsteinn; Johnsson, Anders

journal articleresearch articletext

oai:lup.lub.lu.se:db429f8d-1297-4cfa-8935-57def1890502

Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.

Authors: Otilia Leon
Marianne G Guren
Calin Radu
Adalsteinn Gunnlaugsson
Anders Johnsson
Publication date: 1 January 2015
Publisher: Elsevier
Doi

Abstract

5-fluorouracil (5FU) and mitomycin C (MMC)-based chemoradiotherapy (CRT) is standard treatment for anal squamous cell carcinoma. In this phase I study cetuximab was added and the primary aim was to determine the maximum tolerated dose (MTD) of 5FU and MMC in this combination

Similar works

Full text

Lund University Publications

oai:lup.lub.lu.se:db429f8d-129...

Last time updated on 18/06/2017

This paper was published in Lund University Publications.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.